Semenogelin I expression in myeloma cells can be upregulated pharmacologically

Leukemia Research

Volumn 32, Issue 12, 2008, Pages 1889-1894

  Zhang, Yana ^a,b   Wang, Zhiqing ^a,b   Zhang, Jian ^a,b   Farmer, Benjamin ^a,b   Lim, Seah H ^a,b  

^a Landstuhl Regional Medical Center   (United States)

^b TEXAS ONCOLOGY   (United States)

Author keywords

5 Azacytidine; CT antigen; IL 4; IL 6; Semenogelin I

Indexed keywords

AZACITIDINE; CANCER TESTIS ANTIGEN; DINUCLEOTIDE; INTERLEUKIN 4; INTERLEUKIN 6; SEMENOGELIN I; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CPG ISLAND; HUMAN; HUMAN CELL; METHYLATION; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

AZACITIDINE; BONE MARROW; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-4; INTERLEUKIN-6; MALE; MULTIPLE MYELOMA; PLASMIDS; PROMOTER REGIONS, GENETIC; RESTRICTION MAPPING; SEMEN; SEMINAL VESICLE SECRETORY PROTEINS; TRANSFECTION; UP-REGULATION;

EID: 51649108803     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.03.036     Document Type: Article

References (17)

1. De Lamirande E., Yoshida K., Yoshiike T.M., Iwamoto T., and Gagnon C. Semenogelin, the main protein of semen coagulum, inhibits human sperm capacitation by interfering with the superoxide anion generated during this process. J Androl 22 (2001) 672-679
2. Lilja H., Abrahamsson P.A., and Lundwall A. Semenogelin, the predominant protein in human semen primary structure and identification of closely related protein in the male accessory sex glands and on the spermatozoa. J Biol Chem 264 (1989) 1894-1900
3. Ulvsback M., Lazure C., Lilja H., Spurr N.K., Rao V.V., Loffler C., et al. Gene structure of semenogelin I and II The predominant proteins in human semen are encoded by two homologous genes on chromosome 20. J Biol Chem 267 (1992) 18080-18084
4. Asimakopoulos F.A., White N.J., Nacheva E., and Green A.R. Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes. Blood 84 (1994) 3086-3094
5. Lundwall A., Bjartell A., Olsson A.Y., and Malm J. Semenogelin I and II, the predominant human seminal plasma proteins, are also expressed in non-genital tissues. Mol Human Reprod 8 (2002) 805-810
6. Boniha V.L., Rayborn M.E., Shadrach K., Lundwall A., Malm J., Bhattacharya S.K., et al. Characterization of semenogelin proteins in the human retina. Exp Eye Res 83 (2006) 120-127
7. Rodriguez R.G., Panizo-Santos A., Cashel J.A., Krutzsch H.C., Merino M.J., and Roberts D.D. Semenogelins are ectopically expressed in small cell lung carcinoma. Clin Cancer Res 7 (2001) 854-860
8. Zhang Y., Wang Z., Liu H., Giles F.J., and Lim S.H. Pattern of gene expression and immune responses to semenogelin 1 in chronic hematologic malignancies. J Immunother 26 (2003) 461-467
9. Bert A., Virgili A., Errico G., Vespi G., Lago G., and Cavazzana A. Expression of seminal vesicle-specific antigen in serum of lung tumor patients. J Forensic Sci 50 (2005) 1114-1115
10. Wang Z., Zhang Y., Ramsahoye B., Bowen D., and Lim S.H. Sp17 gene expression in tumor cells is regulated by promoter methylation. Brit J Cancer 91 (2004) 1597-1603
11. Wang Z., Zhang J., Zhang Y., and Lim S.H. SPAN-Xb expression in myeloma cells is dependent on promoter hypomethylation and can be upregulated pharmacologically. Int J Cancer 118 (2006) 1436-1444
12. Wang Z., Zhang J., Zhang Y., Srivenugopal K.S., and Lim S.H. SPAN-XB core promoter sequence is regulated in myeloma cells by specific CpG dinucleotides assocaited with the MeCP2 protein. Int J Cancer 119 (2006) 2878-2884
13. Sigalotti L., Coral S., Altomonte M., Natali L., Gaudino G., Cacciotti P., et al. Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Brit J Cancer 86 (2002) 979-982
14. Ng M.H., Chung Y.F., Lo K.W., Wickham N.W., Lee J.C., and Huang D.P. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 89 (1997) 2500-2506
15. Ng M.H., Wong I.H., and Lo K.W. DNA methylation changes and multiple myeloma. Leuk Lymphoma 34 (1999) 463-472
16. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21 (2002) 5427-5440
17. Egger G., Liang G., Aparicio A., and Jones P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429 (2004) 457-463